| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Clorprenaline targets the β₂-adrenergic receptor (β₂-AR). As an agonist, it binds to and activates these receptors, which are primarily located on bronchial smooth muscle cells. This activation leads to a signaling cascade that results in smooth muscle relaxation, bronchodilation, and improved airflow. It has also been investigated for potential cardiovascular applications due to its mild β₁ activity. It is classified under the Adrenergic Receptor target pathway.
|
|---|---|
| ln Vitro |
In vitro, Clorprenaline acts as a selective agonist of the β₂-adrenergic receptor. Its activity is typically measured by its ability to induce relaxation of isolated bronchial smooth muscle preparations or by its ability to increase cAMP levels in cells expressing the β₂-AR. Its potency and efficacy are compared to other β-agonists. It has also been investigated as a potential lean meat-boosting feed additive.
|
| ln Vivo |
In vivo, Clorprenaline is used as a bronchodilator to relieve symptoms of asthma, chronic bronchitis, and other obstructive airway diseases. Its clinical application is based on its ability to relax bronchial smooth muscle and improve airflow. It may also have mild cardiovascular effects due to its partial β₁ activity. In veterinary applications, it has been studied as a feed additive.
|
| Enzyme Assay |
In vitro non-cell receptor binding assays for Clorprenaline typically involve measuring its binding affinity to the β₂-adrenergic receptor. This is done using radioligand binding studies where the compound competes with a labeled ligand (e.g., [³H]CGP-12177) for binding to the receptor in membrane preparations. Its functional activity (agonism) can be assessed in a cell-free system by measuring its ability to stimulate GTPγS binding.
|
| Cell Assay |
In vitro cell-based assays for Clorprenaline use cell lines that endogenously or heterologously express the β₂-adrenergic receptor. Cells are treated with the compound, and the activation of the receptor is measured by quantifying the accumulation of its downstream second messenger, cyclic AMP (cAMP). The compound's potency (EC₅₀) and efficacy (maximal response) are determined from dose-response curves.
|
| Animal Protocol |
In vivo animal studies for Clorprenaline typically use models of bronchoconstriction, such as histamine- or methacholine-induced bronchospasm in guinea pigs or other rodents. The compound is administered (often by inhalation or intravenously), and its ability to reverse bronchoconstriction is measured. These studies help to characterize its bronchodilator efficacy and duration of action.
|
| ADME/Pharmacokinetics |
Clorprenaline has a molecular weight of 213.70 g/mol and a molecular formula of C₁₁H₁₆ClNO. It is a synthetic compound. As a small, lipophilic molecule, it is expected to be well-absorbed after oral or inhaled administration. It should be stored protected from light. Detailed pharmacokinetic parameters are available from clinical and preclinical studies but are not detailed in the provided search results.
|
| Toxicity/Toxicokinetics |
Clorprenaline is generally well-tolerated, but as a β-agonist, it can cause side effects such as tachycardia, tremors, and nervousness, particularly at higher doses. Its reduced cardiovascular side effects compared to non-selective agonists make it more suitable for respiratory therapy. It is not intended for human therapeutic use without a prescription.
|
| References |
J Pharm Biomed Anal.2005 Jun 1;38(1):166-72. |
| Additional Infomation |
1-(2-Chlorophenyl)-2-isopropylaminoethanol is a member of the chlorobenzene class of compounds. It is a compound in which chlorobenzene is substituted at the 2-position with 1-hydroxy-2-[(propyl-2-yl)amino]ethyl. It is a member of the chlorobenzene class, ethanolamine class, and secondary amino class of compounds.
Clorprenaline is a synthetic β₂-adrenergic receptor agonist used as a bronchodilator to treat asthma and COPD. It is also known as 1-(2-Chlorophenyl)-2-propan-2-ylamino-ethanol. It offers reduced cardiovascular side effects compared to non-selective agonists. It has also been investigated as a feed additive. It is not currently approved for clinical use in many countries and is primarily used in research. |
| Molecular Formula |
C11H16CLNO
|
|---|---|
| Molecular Weight |
213.71
|
| Exact Mass |
213.092
|
| CAS # |
3811-25-4
|
| Related CAS # |
Clorprenaline-d6;1648796-40-0
|
| PubChem CID |
2810
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
329.7±27.0 °C at 760 mmHg
|
| Flash Point |
153.2±23.7 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.537
|
| LogP |
2.18
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
14
|
| Complexity |
163
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)NCC(C1=CC=CC=C1Cl)O
|
| InChi Key |
SSMSBSWKLKKXGG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H16ClNO/c1-8(2)13-7-11(14)9-5-3-4-6-10(9)12/h3-6,8,11,13-14H,7H2,1-2H3
|
| Chemical Name |
1-(2-chlorophenyl)-2-(propan-2-ylamino)ethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~584.93 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6792 mL | 23.3962 mL | 46.7924 mL | |
| 5 mM | 0.9358 mL | 4.6792 mL | 9.3585 mL | |
| 10 mM | 0.4679 mL | 2.3396 mL | 4.6792 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
